News

In our Sustainability Report 2024, we demonstrate how we increasingly recognise the crucial link between ESG and business performance, highlighting our sustainability efforts the past year.

In 2024, the Abacus Medicine Group celebrated 20 years of strong, organic growth. Revenue grew 23% to EUR 1,487 million, while EBITDA reached a record high of EUR 50.5 million and the Free cash flow was EUR 26.4 million.

Alette Verbeek and Sharon Curran are being nominated by the main shareholders, Wagner Family Holding ApS (approx. 58% ownership) and Chr. Augustinus Fabrikker Aktieselskab (approx. 35% ownership). All shareholders have been invited to an extraordinary general meeting on 4th October, 2024.

The Abacus Medicine Group celebrates its 20th anniversary. We have experienced a fantastic development through 20 years of uninterrupted growth. With your help, we have grown into one of the 100 largest companies in Denmark, and have been the only Danish company to receive 12 gazelles from Børsen.

Under the terms of the agreement, Mirum Pharmaceuticals has appointed Abacus Medicine Pharma Services to exclusively promote, market, sell, distribute, and commercialize LIVMARLI in the territory of Denmark, Finland, Iceland, Norway, and Sweden.

In 2023, sustainability became an enabler of our Access26 strategy – an important step towards ensuring a deeper integration of sustainability in all our processes and operations. Throughout the year, we also prepared for the upcoming Corporate Sustainability Reporting Directive, under which we need to report in 2026.